Treats Chagas disease (American Trypanosomiasis) caused by Trypanosoma cruzi. Sold as Lampit. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Nifurtimox (sold as Lampit), first approved Aug 6, 2020, with 1 new use approved and 0 published complete response letters.
| Study | Phase | Status | Posted |
|---|---|---|---|
| An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About the Risk of Pregnancy Complications and About the Mother's and Baby's HealthChagas Disease · Bayer | — | Not yet recruiting | Jul 28, 2022 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Aug 6, 2020 | LampitNDA 213464 · New molecular entity | Bayer Healthcare | 4 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Bayer Healthcare